Product
Cisplatin + Pembrolizumab + Pemetrexed
1 clinical trial
1 indication
Indication
Lung CancerClinical trial
QUILT 2.023: A Phase 3, Open-Label, 3-Cohort Randomized Study of N-803, in Combination With Current Standard of Care VS Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic NSCLC.Status: Active (not recruiting), Estimated PCD: 2025-10-01